Key takeaways<\/h2>\n\n- \n
Trulicity (dulaglutide) and Victoza (liraglutide) are injectable glucagon-like peptide-1 receptor agonists used in the treatment of Type 2 diabetes, with Trulicity administered weekly and Victoza daily.<\/p>\n<\/li>\n
- \n
Both medications are effective in lowering blood sugar levels and reducing cardiovascular events in Type 2 diabetes patients, with no significant difference in their efficacy or safety profiles.<\/p>\n<\/li>\n
- \n
Common side effects include gastrointestinal issues such as nausea and diarrhea, and both medications require caution in patients with a history of pancreatitis or renal impairment.<\/p>\n<\/li>\n
- \n
The choice between Trulicity and Victoza may depend on patient preference for once-weekly versus once-daily injections, as well as individual insurance coverage and cost considerations.<\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
Drug overview & main differences<\/a> | Conditions treated<\/a> | Efficacy<\/a> | Insurance coverage and cost comparison<\/a> | Side effects<\/a> | Drug interactions<\/a> | Warnings<\/a> | FAQ<\/a><\/p>\nTrulicity and Victoza are two prescription injectable drugs indicated in the treatment of Type 2 diabetes mellitus (T2DM). In the United States, approximately 1 in 10 people have a form of<\/span> diabetes<\/span><\/a>, and it is estimated that 90% of those are <\/span>Type 2 diabetes<\/span>. People with Type 1 diabetes are unable to produce insulin, a hormone needed to maintain blood sugar balance in their cells for energy. Type 2 diabetics are able to produce insulin, but their body doesn\u2019t respond to it appropriately. This allows blood sugar levels to get too high. There are serious health consequences associated with high blood sugar including heart disease, kidney disease, and vision loss.<\/span><\/p>\nTrulicity (dulaglutide) and Victoza (liraglutide) belong to a class of medications known as glucagon-like peptide-1 receptor agonists, often referred to as <\/span>GLP-1s<\/span>. This is a relatively new class of medications in the treatment of Type 2 diabetes. Other options in this class include <\/span>Bydureon<\/span> (exenatide), <\/span>Byetta<\/span> (exenatide), and <\/span>Ozempic<\/span> (semaglutide). For the purposes of this review, we will specifically compare Trulicity and Victoza<\/span><\/p>\nWhat are the main differences between Trulicity vs. Victoza<\/h2>\n
Trulicity<\/span> (dulaglutide) is a glucagon-like peptide-1 receptor agonist. It is a once-weekly injectable subcutaneous drug produced by Eli Lilly available only by prescription. GLP-1s work by mimicking the structure of naturally occurring hormones in the human body known as incretin hormones. When you eat food, your stomach releases these hormones, and they, in turn, stimulate the release of insulin from the pancreas. Insulin helps control blood sugar levels by helping cells absorb glucose to be used for energy. T2DM patients often lack enough incretin hormones to stimulate this process, and that is why the GLP-1 receptor agonists are effective at helping them manage their blood sugar. Trulicity is available in 4 different doses: 0.75 mg\/0.5 ml, 1.5 mg\/0.5 ml, 3 mg\/0.5 ml, and 4.5 mg\/0.5 ml. Trulicity is provided in single-use injection pens and is intended for once-weekly injections only.<\/span><\/p>\nVictoza<\/span> (liraglutide) is a once-daily GLP-1 agonist produced by Novo Nordisk which is also a subcutaneous injectable and available by prescription only. Both Trulicity and Victoza are considered long-acting GLP-1 agonists, but the biggest difference is that Trulicity is given once weekly and Victoza is given once daily. Victoza is available in 18 mg\/3 ml pens that can be used to administer 3 different doses: 0.6 mg, 1.2 mg, and 1.8 mg.<\/span><\/p>\n
Trulicity (dulaglutide) and Victoza (liraglutide) are injectable glucagon-like peptide-1 receptor agonists used in the treatment of Type 2 diabetes, with Trulicity administered weekly and Victoza daily.<\/p>\n<\/li>\n
Both medications are effective in lowering blood sugar levels and reducing cardiovascular events in Type 2 diabetes patients, with no significant difference in their efficacy or safety profiles.<\/p>\n<\/li>\n
Common side effects include gastrointestinal issues such as nausea and diarrhea, and both medications require caution in patients with a history of pancreatitis or renal impairment.<\/p>\n<\/li>\n
The choice between Trulicity and Victoza may depend on patient preference for once-weekly versus once-daily injections, as well as individual insurance coverage and cost considerations.<\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n
Drug overview & main differences<\/a> | Conditions treated<\/a> | Efficacy<\/a> | Insurance coverage and cost comparison<\/a> | Side effects<\/a> | Drug interactions<\/a> | Warnings<\/a> | FAQ<\/a><\/p>\n Trulicity and Victoza are two prescription injectable drugs indicated in the treatment of Type 2 diabetes mellitus (T2DM). In the United States, approximately 1 in 10 people have a form of<\/span> diabetes<\/span><\/a>, and it is estimated that 90% of those are <\/span>Type 2 diabetes<\/span>. People with Type 1 diabetes are unable to produce insulin, a hormone needed to maintain blood sugar balance in their cells for energy. Type 2 diabetics are able to produce insulin, but their body doesn\u2019t respond to it appropriately. This allows blood sugar levels to get too high. There are serious health consequences associated with high blood sugar including heart disease, kidney disease, and vision loss.<\/span><\/p>\n Trulicity (dulaglutide) and Victoza (liraglutide) belong to a class of medications known as glucagon-like peptide-1 receptor agonists, often referred to as <\/span>GLP-1s<\/span>. This is a relatively new class of medications in the treatment of Type 2 diabetes. Other options in this class include <\/span>Bydureon<\/span> (exenatide), <\/span>Byetta<\/span> (exenatide), and <\/span>Ozempic<\/span> (semaglutide). For the purposes of this review, we will specifically compare Trulicity and Victoza<\/span><\/p>\n Trulicity<\/span> (dulaglutide) is a glucagon-like peptide-1 receptor agonist. It is a once-weekly injectable subcutaneous drug produced by Eli Lilly available only by prescription. GLP-1s work by mimicking the structure of naturally occurring hormones in the human body known as incretin hormones. When you eat food, your stomach releases these hormones, and they, in turn, stimulate the release of insulin from the pancreas. Insulin helps control blood sugar levels by helping cells absorb glucose to be used for energy. T2DM patients often lack enough incretin hormones to stimulate this process, and that is why the GLP-1 receptor agonists are effective at helping them manage their blood sugar. Trulicity is available in 4 different doses: 0.75 mg\/0.5 ml, 1.5 mg\/0.5 ml, 3 mg\/0.5 ml, and 4.5 mg\/0.5 ml. Trulicity is provided in single-use injection pens and is intended for once-weekly injections only.<\/span><\/p>\n Victoza<\/span> (liraglutide) is a once-daily GLP-1 agonist produced by Novo Nordisk which is also a subcutaneous injectable and available by prescription only. Both Trulicity and Victoza are considered long-acting GLP-1 agonists, but the biggest difference is that Trulicity is given once weekly and Victoza is given once daily. Victoza is available in 18 mg\/3 ml pens that can be used to administer 3 different doses: 0.6 mg, 1.2 mg, and 1.8 mg.<\/span><\/p>\nWhat are the main differences between Trulicity vs. Victoza<\/h2>\n